N-terminal PEGylation of human serum albumin and investigation of its pharmacokinetics and pulmonary microvascular retention

BioScience Trends

Volumn 6, Issue 2, 2012, Pages 81-88

  Zhao, Ting ^a   Yang, Yang ^a   Zong, Aizhen ^a   Tan, Haining ^a   Song, Xinlei ^a   Meng, Shuo ^a   Song, Chunxia ^b   Pang, Guangli ^c   Wang, Fengshan ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c Shandong Taibang Biological Products Co Ltd   (China)

Author keywords

Human serum albumin; N terminal pegylation; Pharmacokinetics; Vascular permeability

Indexed keywords

MACROGOL DERIVATIVE; SERUM ALBUMIN;

ANIMAL; ARTICLE; CAPILLARY PERMEABILITY; CHEMISTRY; CIRCULAR DICHROISM; HUMAN; MOUSE;

ANIMALS; CAPILLARY PERMEABILITY; CIRCULAR DICHROISM; HUMANS; MICE; POLYETHYLENE GLYCOLS; SERUM ALBUMIN;

EID: 84862312046     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2012.v6.2.81     Document Type: Article

References (31)

1. Mingetti PP, Ruffner DE, Kuang WJ, Dennison OE, Hawkins JW, Beattie WG, Dugaiczyk A. Molecular structure of the human albumin gene is revealed by nucleotide sequence within q11e22 of chromosome 4. J Biol Chem. 1986; 261:6747-6757.
2. Kobayashi K. Summary of recombinant human serum albumin development. Biologicals. 2006; 34:55-59.
3. Groeneveld AB, Teule GJ, Bronsveld W, van den Bos GC, Thijs LG. Increased systemic microvascular albumin flux in septic shock. Intensive Care Med. 1987; 13:140-142.
4. Bradley JA, Cunningham KJ, Jackson VJ, Hamilton DNH, Ledingham IA. Serum protein levels in critically Ill surgical patients. Intensive Care Med. 1981; 7:291-295.
5. Waterhouse C, Fenninger LD, Keutmann EH. Nitrogen exchange and caloric expenditure in patients with malignant neoplasms. Cancer. 1951; 4:500-514.
6. Fleck A, Raines G, Hawker F, Trotter J, Wallace PI, Ledingham IM, Calman KC. Increased vascular permeability: A major cause of hypoalbuminaemia in disease and injury. Lancet. 1985; 1:781-784.
7. Marx G. Fluid therapy in sepsis with capillary leakage. Eur J Anaesthesiol. 2003; 20: 429-442.
8. Matsushita S, Chuang VT, Kanazawa M, Tanase S, Kawai K, Maruyama T, Suenaga A, Otagiri M. Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin. Pharm Res. 2006; 23:882-891.
9. Doweiko JP, Nompleggi DJ. Role of albumin in human physiology and pathophysiology. JPEN J Parenter Enteral Nutr. 1991; 15:207-211.
10. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227:680-685.
11. Kathmann EEL, Davis DAD, McCormick CL. Synthesis and solution behavior of terpolymers of acrylic acid, acrylamide, and the zwitterionic monomer 3-[(2-acrylamido-2-methylpropyl)dimethylammonio]-1-propanesulfonate. Macromolecules. 1994; 27:3156-3161.
12. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978; 80:849-857.
13. Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, Kwon YG, Kim TW, Webster KA, Nechustan H, Shin SU. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther. 2005; 4:956-967.
14. Szarka RJ, Wang N, Gordon L, Nation PN, Smith RH. A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation. J Immunol Methods. 1997; 202:49-57.
15. Monsigny M, Roche AC, Midoux P. Uptake of neoglycoproteins via membrane lectin(s) of L1210 cells evidenced by quantitative flow cytofluorometry and drug targeting. Biol Cell. 1984; 51:187-196.
16. Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev. 2002; 54:477-485.
17. Cantin AM, Woods DE, Cloutier D, Dufour EK, Leduc R. Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha1 proteinase inhibitor. Am J Respir Cell Mol Biol. 2002; 27:659-665.
18. Zhang H, Sun GY. LPS induces permeability injury in lung microvascular endothelium via AT(1) receptor. Arch Biochem Biophys. 2005; 441:75-83.
19. Mizgerd JP, Skerrett SJ. Animals models of human pneumonia. AmJ Physiol Lung CellMol Physiol. 2008; 294:387-398.
20. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001; 135:149-164.
21. Cochrane Injuries Group. Human albumin administration in critically ill patients: Systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ. 1998; 317:235-240.
22. Veronese F, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005; 10:1451-1458.
23. Kozlowski A, Harris JM. Improvements in protein PEGylation: Pegylated interferons for treatment of hepatitis C. J Controlled Release. 2001; 72:217-224.
24. Schnitzer JE, Oh P. Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. J Biol Chem. 1994; 269:6072-6082.
25. Schnitzer JE, Bravo J. High affinity binding, endocytosis, and degradation of conformationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors. J Biol Chem. 1993; 268:7562-7570.
26. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000; 85:599-610.
27. Manelli JC. Is albumin administration useful in critical care for burnt patients? Ann Fr Anesth Reanim. 1996; 15:507-513.
28. Groeneveld AB, Bronsveld W, Thijs LG. Hemodynamic determinants of mortality in human septic shock. Surgery. 1986; 99:140-153.
29. Zhao T, Cheng YN, Tan HN, Liu JF, Xu HL, Pang GL, Wang FS. Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs halflife and improves intravascular retention in mice. Biol Pharm Bull. 2012; 35:280-288.
30. Kaminskas LM, Boyd BJ, Karellas P, Krippner GY, Lessene R, Kelly B, Porter CJ. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. Mol Pharm. 2008; 5:449-463.
31. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci. 1994; 83:601-606.